Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers

Alcoholism: Clinical and Experimental Research

Volumn 32, Issue 7, 2008, Pages 1159-1166

  Arias, Albert J ^a   Armeli, Stephen ^b   Gelernter, Joel ^c   Covault, Jonathan ^a   Kallio, Antero ^d   Karhuvaara, Sakari ^d   Koivisto, Tiina ^d   Mäkelä, Rauno ^e   Kranzler, Henry R ^a,f  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Biotie Therapies Corp   (Finland)

^e A klinikkasaatio Finland   (Finland)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Alcohol treatment; Nalmefene; OPRD1; OPRK1; OPRM1; Pharmacogenetics

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALMEFENE; PLACEBO; DRUG DERIVATIVE; NALTREXONE; NARCOTIC ANTAGONIST; OPIATE RECEPTOR;

A118G GENE; ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPIATE RECEPTOR GENE; OPRK1 GENE; OPRM1 GENE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; ALCOHOL-RELATED DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, OPIOID; TREATMENT OUTCOME;

EID: 54749152894     PISSN: 01456008     EISSN: 15300277     Source Type: Journal    
DOI: 10.1111/j.1530-0277.2008.00735.x     Document Type: Article

References (60)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
2. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65:135-144.
3. Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S (2004) A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psycho-pharmacol 24:421-428.
4. Arias A, Feinn R, Kranzler HR (2006) Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 83:262-268.
5. Bauer LO, Covault J, Harel O, Das S, Gelernter J, Anton R, Kranzler HR (2008) Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res 31:1780-1787.
6. Beck A, Steer R (1993) Beck Anxiety Inventory Manual. The Psychological Corporation, San Antonio, TX.
7. Beck A, Steer R, Brown G (1996) Beck Depression Inventory, 2nd ed. Manual. The Psychological Corporation, San Antonio, TX.
8. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130-3137.
9. Beyer A, Koch T, Schroder H, Schulz S, Hollt V (2004) Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocyto- sis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 89:553-560.
10. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-9613.
11. Chinn S (2000) A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 19:3127-3131.
12. Chong RY, Oswald L, Yang X, Uhart M, Lin PI, Wand GS (2006) The μ-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31:204-211.
13. Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Lawrence Erlbaum Associates, Hillsdale, NJ.
14. Covault J, Gelernter J, Hesselbrock V, Nellissery M, Kranzler HR (2004) Alle-lic and haplotypic association of GABRA2 with alcohol dependence. Am J Med Genet B Neuropsychiatr Genet 129:104-109.
15. Drobes DJ, Anton RF, Thomas SE, Voronin K (2004) Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res 28:1362-1370.
16. Edenberg HJ, Dick DM, Xuei X, Tian H, Almasy L, Bauer LO, Crowe RR, Goate A, Hesselbrock V, Jones K, Kwon J, Li TK, Nurnberger JI Jr, O'Connor SJ, Reich T, Rice J, Schuckit MA, Porjesz B, Foroud T, Begleiter H (2004) Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations. Am J Hum Genet 74:705-714.
17. Edenberg HJ, Kranzler HR (2005) The contribution of genetics to addiction therapy approaches. Pharmacol Ther 108:86-93.
18. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
19. Enoch MA, Schwartz L, Albaugh B, Virkkunen M, Goldman D (2006) Dimensional anxiety mediates linkage of GABRA2 haplotypes with alcoholism. Am J Med Genet B Neuropsychiatr Genet 141:599-607.
20. Fehr C, Sander T, Tadic A, Lenzen KP, Anghelescu I, Klawe C, Dahmen N, Schmidt LG, Szegedi A (2006) Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis. Psychiatr Genet 16:9-17.
21. First M, Spitzer R, Gibbon M, Williams J (2001) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York State Psychiatric Institute, New York: Biometrics Research.
22. Gal TJ, DiFazio CA, Dixon R (1986) Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40:537-542.
23. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293:1617-1625.
24. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res 31:555-563.
25. Gelernter J, Kranzler HR (2000) Variant detection at the delta opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence. Hum Genet 107:86-88.
26. Gelernter J, Kranzler HR (2008) Genetics of addiction, in Textbook of Substance Abuse Treatment, 4th ed. (Galanter M, Kleber H eds), pp. 17-27. American Psychiatric Press, Inc, Washington, DC.
27. Hernandez-Avila C, Covault J, Wand G, Zhang H, Gelernter J, Kranzler HR (2007) Population-specific effects of the Asn40Asp polymorphism at the m-opioid receptor gene (OPRM1) on HPA axis activation. Pharmacogenet Genomics 17:1031-1038.
28. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B:60-65.
29. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM (2000) Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9:2895-2908.
30. Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S, Kallio A, Oikonen V, Hietala J, Scheinin H (2005) Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30:2245-2253.
31. Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, Kallio A, Makela R (2007) Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol Clin Exp Res 31:1179-1187.
32. Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D (1998) Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). Alcohol Clin Exp Res 22:1359-1362.
33. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734-1739.
34. Lappalainen J, Krupitsky E, Remizov M, Pchelina S, Taraskina A, Zvartau E, Somberg LK, Covault J, Kranzler HR, Krystal JH, Gelernter J (2005) Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res 29:493-498.
35. Lesscher HM, Bailey A, Burbach JP, Van Ree JM, Kitchen I, Gerrits MA (2003) Receptor-selective changes in mu-, delta- and kappa-opioid receptors after chronic naltrexone treatment in mice. Eur J Neurosci 17:1006-1012.
36. Livak KJ, Flood SJ, Marmaro J, Giusti W, Deetz K (1995) Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl 4:357-362.
37. Luo X, Kranzler HR, Zhao H, Gelernter J (2003) Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet 120:97-108.
38. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Man-tero-Atienza E (1994) A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162-1167.
39. Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719-724.
40. McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr (2006) Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res 30:1288-1296.
41. Michel ME, Bolger G, Weissman BA (1985) Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175-177.
42. Miller WR, Tonigan JS, Longabaugh R (1995) The Drinker Inventory of Consequences (DrInC): An instrument for assessing adverse consequences of alcohol abuse. Test Manual (Volume 4, Project MATCH monograph Series). Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.
43. Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC (2007) The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. J Clin Psychopharmacol 27:112-115.
44. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258-268.
45. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552.
46. Oslin DW, Pettinati H, Volpicelli JR (2002) Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes. Am J Geriatr Psychiatry 10:740-747.
47. Oswald LM, Wand GS (2004) Opioids and alcoholism. Physiol Behav 81:339-358.
48. Pierucci-Lagha A, Covault J, Feinn R, Nellissery M, Hernandez-Avila C, Oncken C, Morrow AL, Kranzler HR (2005) GABRA2 alleles moderate the subjective effects of alcohol, which are attenuated by finasteride. Neuropsychopharmacology 30:1193-1203.
49. Ray LA, Hutchison KE (2004) A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 28:1789-1795.
50. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T (2005) Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 40:227-233.
51. Skinner HA, Allen BA (1982) Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol 91:199-209.
52. Sobell L, Sobell M (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption (Litten R, Allen J eds), pp 41-65. Humana Press, Clifton, NJ.
53. Soyka M, Preuss UW, Hesselbrock V, Zill P, Koller G, Bondy B (2008) GABA-A2 receptor subunit gene (GABRA2) polymorphisms and risk for alcohol dependence. J Psychiatr Res 42:184-191.
54. Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev, January 25, CD001867.
55. Volpicelli J, Pettinati HM, McLellan AT, O'Brien CP (2001) Combining Medication and Psychosocial Treatments for Addictions: the BRENDA Approach. Guilford Press, New York.
56. Volpicelli JR, Volpicelli LA, O'Brien CP (1995) Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment. Alcohol Alcohol 30:789-798.
57. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2002) The mu-opioid receptor gene polymorphism (A1 18G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106-114.
58. van den Wildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, van Breukelen GJ (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 31:1-10.
59. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J (2006) Association between two l-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15:807-819.
60. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W (2005) Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A1 18G. J Biol Chem 280:32618-32624.